- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04427475
Prediction of Immunotherapeutic Effect of Advanced Non-small Cell Lung Cancer
June 9, 2020 updated by: Jialei Wang, Fudan University
Study on the Prediction of Immunotherapeutic Effect of Advanced Non-small Cell Lung Cancer by Detection of Plasma Exosomes
To detect the difference of PD-L1 and miRNA expression profiles of exosomes in NSCLC patients before and after immunotherapy, and to explore the potential of plasma exosomes PD-L1 and miRNAs as biomarkers to predict the therapeutic effect of NSCLC on anti-PD-1 / PD-L1.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
200
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Recruiting
- Cancer hospital Fudan University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Sign informed consent.
- The age is greater than or equal to 18 years old.
- There is at least one measurable focus according to the RECIST 1.1 standard
- EGFR / ALK detection is not needed in patients with metastatic (stage IV) EGFR / ALK wild-type NSCLC confirmed by histology or cytology and in patients with squamous cell carcinoma.
- Cohort 1: patients receiving anti-PD-1 (pabolizumab) treatment combined with chemotherapy as the first-line treatment Cohort 2: patients who received the second-line treatment of anti-PD-1 single drug (nafulizumab) for the progress of disease after chemotherapy with platinum containing dual drugs
- ECoG score is 0, 1 or 2.
- No serious blood system, heart, lung, liver and kidney dysfunction and immune deficiency.
- Hemoglobin (HB) ≥ 9g / dl; leukocyte (WBC) ≥ 3 * 109 / L; neutrophil (ANC) ≥ 1.5 * 109 / L; platelet (PLT) ≥ 75 * 109 / L.
- Men or women of childbearing age are willing to take contraceptive measures in the experiment.
- Estimated survival time ≥ 3 months.
Exclusion Criteria:
- Histologically, small cell and non-small cell mixed lung cancer.
- Pregnant or nursing women.
- Any unresponsive > CTCAE Level 2 toxicity caused by past anti-tumor treatment
- Serum creatinine clearance < 30 ml / min (calculated by Cockcroft Gault formula)
Liver dysfunction, defined as:
- Serum (total) bilirubin > 1.5 × upper limit of normal value (ULN)
- Serum AST / SGOT or ALT / SGPT > 2.5 × ULN (liver metastasis > 5 × ULN)
- Alkaline phosphatase level > 2.5 × ULN (liver metastasis > 5 × ULN, or bone) at baseline Transfer patients > 10 × ULN)
- Have a history of uncontrollable or symptomatic angina, arrhythmia or congestive heart failure.
- Symptomatic brain metastasis or meningeal metastasis.
- In the past 5 years, she has had or is suffering from other histological types of malignant tumors, except for cervical carcinoma in situ and fully treated skin basal cell carcinoma or squamous cell carcinoma.
- Have active, or have had and may recur autoimmune diseases. However, subjects with type I diabetes, hypothyroidism requiring hormone replacement therapy only, skin diseases without systemic treatment (such as vitiligo, psoriasis or alopecia), or no relapse without external triggers are expected.
- Diagnosis of immunodeficiency or systemic hormone therapy (e.g., hormone therapy equivalent to > 10 mg prednisone per day) or any other form of immunosuppressive therapy within 7 days before the first administration.
- Patients with known history of human immunodeficiency virus (HIV) infection and / or acquired immunodeficiency syndrome. Subjects with active hepatitis B or active hepatitis C
- Grade 2 pneumonia caused by radiotherapy and chemotherapy (grade 2 pneumonia without systemic hormone treatment recovers to grade 1 or below within 14 days, if the researcher judges that there is no risk of recurrence, it can be included in the group for screening).
- Have interstitial lung disease and the disease has symptoms.
- During the study period, radiotherapy is planned for the target focus.
- Plan to use other anti-tumor therapy during the study period.
- Patients with serious or uncontrolled systemic diseases who are not suitable for the study or may affect the compliance of the other party's case. Subjects' complications or other conditions may affect compliance with the protocol or may not be suitable for the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: pabolizumab
Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles.
|
100 patients with stage IV EGFR / ALK wild-type NSCLC (squamous cell carcinoma patients do not need to be detected) who received anti-PD-1 (pabolizumab) treatment combined with chemotherapy as the first-line treatment were enrolled in the center.
Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles.
At the same time, plasma samples were collected at key nodes until the patient's progress.
|
Other: nafulizumab
Baseline plasma samples were collected before the treatment, and the efficacy was evaluated once every two treatment cycles.
|
nafulizumab
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PD-L1 expression profiles of exosomes
Time Frame: through study completion, an average of 1 year
|
detect the difference of PD-L1 expression profiles of exosomes in NSCLC patients before and after immunotherapy
|
through study completion, an average of 1 year
|
miRNA expression profiles of exosomes
Time Frame: through study completion, an average of 1 year
|
detect the difference of miRNA expression profiles of exosomes in NSCLC patients before and after immunotherapy
|
through study completion, an average of 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 8, 2020
Primary Completion (Anticipated)
December 31, 2021
Study Completion (Anticipated)
December 31, 2022
Study Registration Dates
First Submitted
June 8, 2020
First Submitted That Met QC Criteria
June 9, 2020
First Posted (Actual)
June 11, 2020
Study Record Updates
Last Update Posted (Actual)
June 11, 2020
Last Update Submitted That Met QC Criteria
June 9, 2020
Last Verified
June 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MIRNA-SEP-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NSCLC Patients
-
AstraZenecaCompletedLocally Advanced or Metastatic EGFR(+) NSCLC PatientsChina
-
AstraZenecaCompletedCaucasian Patients With EGFR Mutation Positive Advanced NSCLCBulgaria, Italy, Poland, Spain, Turkey, United Kingdom, Romania, Norway, Hungary, Portugal, Greece, Switzerland, France
-
AstraZenecaCompletedT790M Positive NSCLC PatientsChina
-
Cancer Institute and Hospital, Chinese Academy...RecruitingUntreated Advanced NSCLC Patients | FISH Identified ALK Fusion Positive or NegativeChina
-
Centre Francois BaclesseHoffmann-La Roche; Groupe Francais De Pneumo-CancerologieTerminatedNSCLC Patients With EGFR Activating MutationFrance
-
Li Zhang, MDRecruitingThe Diagnosis Was ALK Positive NSCLC | Second Generation ALK-TKI is Resistant | Efficacy of Ensatinib in This Subset of PatientsChina
-
Shanghai Henlius BiotechCompleted
-
The Netherlands Cancer InstituteEnrolling by invitation
-
Centre Oscar LambretUniversity Hospital, LilleTerminated
Clinical Trials on pabolizumab
-
Peking University Cancer Hospital & InstituteRecruitingGastric Cancer | Gastric AdenocarcinomaChina
-
Women's Hospital School Of Medicine Zhejiang UniversityNot yet recruiting